Efficacy of Novel SGLT2 Inhibitors in Slowing Progression of Diabetic Nephropathy: A Multicenter Clinical Trial

24^th Annual Conference on Urology and Nephrological Disorders

April 10-11, 2025 | Webinar

Robert J. Feldman

Johns Hopkins University School of Medicine, USA

Scientific Tracks Abstracts: J Nephrol Ther

Abstract :

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently emerged as promising agents to reduce hyperglycemia and protect kidney function. This multicenter, double-blind clinical trial evaluated the efficacy and safety of a new SGLT2 inhibitor in 400 patients with type 2 diabetes and early-stage DN over 24 months. The primary outcome was decline in estimated glomerular filtration rate (eGFR). Secondary outcomes included albuminuria reduction, blood pressure control, and adverse events. Results demonstrated a significant 30% reduction in eGFR decline compared to placebo (p < 0.001), accompanied by improved albuminuria and blood pressure parameters. The drug was well tolerated with a low incidence of genitourinary infections. This study supports the use of SGLT2 inhibitors as an effective strategy to delay DN progression and improve renal outcomes in diabetic patients.

Biography :

Robert J. Feldman is a nephrologist with over 20 years of experience researching diabetic kidney disease and novel therapeutic interventions. He has led multiple large-scale clinical trials and serves on several guideline committees for chronic kidney disease management.